SOX9基因在前列腺癌与前列腺增生中的表达以及意义

SOX9 expression and clinical significance in prostate cancer and benign prostate hyperplasia

目的通过检测SOX9基因在前列腺癌和前列腺增生组织中的表达情况,探讨SOX9在前列腺癌中的分子机制和临床意义。方法使用实时荧光定量PCR方法检测SOX9基因在54例前列腺癌和52例前列腺增生组织中的表达,并对比在前列腺癌患者的年龄,血清PSA水平,Gleason评分,临床分期和远处转移的表达差异,再通过免疫组化方法验证SOX9在前列腺癌和前列腺增生中的表达差异。结果使用实时荧光定量PCR检测SOX9基因,发现其在前列腺癌中表达值为(8.94±0.75),前列腺增生中表达值为(5.46±0.69),有显著性差异(P<0.05)。SOX9基因表达随着前列腺癌患者血清PSA水平、Gleason score、肿瘤TNM分期升高而升高,有远处转移比无远处转移表达升高(P<0.05),而与患者年龄无明显相关(P>0.05)。免疫组化结果显示前列腺癌组织和前列腺增生组织中SOX9阳性表达率分别为92.6%和15.4%,差异有显著性(P<0.05)。结论SOX9基因表达检测有助于前列腺癌的诊断和指导前列腺癌的恶性程度分期。

【Objective】 By detecting the SOX9 gene expression in prostate cancer and benign prostate hyperplasia tissue,to explore SOX9 molecular mechanism and clinical significance in prostate cancer.【Methods】 Using real-time fluorescence quantitative PCR to detect the expression of SOX9 gene in 54 patients with prostate cancer and 52 patients with benign prostatic hyperplasia tissue.Contrast in the age of patients with prostate cancer,serum PSA level,Gleason score,clinical stage and distant metastasis differentially expressed,and then verify by immunohistochemical SOX9 expression differences in prostate cancer and benign prostatic hyperplasia.【Results】 The expression of SOX9 gene value in the prostate cancer was（8.94±0.75）,prostatic hyperplasia was（5.46±0.69）,and statistically significant（P ＆lt;0.05）.SOX9 gene expression increased with prostate cancer in patients with serum PSA level,Gleason score,TNM stage increased distant metastasis than without distant metastasis expression was increased（P ＆lt;0.05）,while no significant correlation with patient age（P ＆gt;0.05）.Immunohistochemical results showed that SOX9 positive expression rates of prostate cancer and prostatic hyperplasia were 92.6% and 15.4%,statistical differences（P ＆lt;0.05）.【Conclusion】 SOX9 gene expression contribute to the diagnosis of prostate cancer and the guidance to the degree of malignancy of prostate cancer staging.